A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00708539

Enrollment

2686

Registered

2008-07-02

Start date

2006-04-30

Completion date

2008-12-31

Last updated

2008-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF - Luteal Phase Support After Embryo Transfer

Brief summary

To compare the effect of Crinone 8% administered once daily versus other vaginal progesterone in terms of ongoing pregnancy rate 5 weeks after embryo transfer as well as patient convenience.

Interventions

DRUGprogesterone

90 mg, vaginal, once daily

DRUGProgesterone

200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* 18-40 years * Regular menstrual cyclus 25-35 days * both ovaries present * No more than 2 previous IVF attempts * Have given written informed consent

Exclusion criteria

* More than 2 previous attempts * Known drug abuse * Known allergies to the study medication * No embryo transfer performed in the study cycle * Previous participating in the study

Design outcomes

Primary

Measure	Time frame
Equivalence in ongoing pregnancy per embryo transfer between the two groups	week 5 after embryo tranfer

Secondary

Measure	Time frame
Convenience for the patient	the treatment period (from the day of embryo transfer and 19 days ahead)

Countries

Denmark, Sweden

Contacts

Primary ContactSvend Lindenberg

svend@lindenberg.dk004533257000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026